HANDYLAB, INC. TO PARTNER WITH NANOGEN, INC.
Nanogen, Inc. (Nasdaq: NGEN), developer of in vitro diagnostic products announced it has been awarded a new $10.4 million, two-year contract from the U.S. Centers for Disease Control and Prevention (CDC) to develop a multi-analyte molecular diagnostic assay for Influenza.
SAN DIEGO - Nanogen, Inc. (Nasdaq: NGEN), developer of in vitro diagnostic products announced it has been awarded a new $10.4 million, two-year contract from the U.S. Centers for Disease Control and Prevention (CDC) to develop a multi-analyte molecular diagnostic assay for Influenza. The molecular diagnostic test will be developed in partnership with the Medical College of Wisconsin (MCW) and HandyLab, Inc. of Ann Arbor, MI. The test will be significantly more sensitive than current rapid flu tests and is expected to be conducted in less than half the time it takes to run current molecular tests. These tests are intended as a key component of the CDC's two-pronged approach to quickly identify and respond to a potential flu pandemic.
The Nanogen proposal to the CDC included the use of Nanogen's proprietary MGB probe technology for real-time PCR and anticipates the use of off-the-shelf instrumentation for sample handling and detection, including the HandyLab Raider system, a microfluidic real-time PCR technology, which will significantly shorten time to result.
"Our collaboration with Nanogen on this project validates Raider's performance for microfluidic real-time PCR technology" said Mark Powelson, HandyLab's Vice President of Sales and Marketing, "Our technology contribution to this project is anticipated to redefine the way respiratory testing is done."
###
About HandyLab: HandyLab is dedicated to the development, manufacture and sale of novel molecular diagnostic products based on patented and proprietary microfluidic, miniaturized real-time PCR and nucleic acid extraction technologies.
www.handylab.com HandyLab, Inc 5230 South State Road Ann Arbor, MI 48108www.nanogen.com
(p) 734 663 4719
(f) 734 663 7437
About Nanogen, Inc.: Nanogen, Inc. develops diagnostic products that enable physicians to deliver improved patient care. Its products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and a range of infectious diseases. The company's products include molecular diagnostic kits and reagents, and kits for rapid point-of-care testing. Nanogen has pioneered the development of biomarkers, molecular biology technologies and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen's website at www.nanogen.com